Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vilazodone in pediatric MDD
NCT02372799Phase 3Completed
- Sponsor
- Forest Laboratories
- Start
- Feb 2015
- Primary completion
- Sep 2018
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial of vilazodone in major depressive disorder (MDD) (3 arms), sponsored by Forest Laboratories. Primary endpoint: Children's Depression Rating Scale-Revised Total Score at 8 weeks. Started Feb 2015; status: completed.
02
Drugs
vilazodone
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT02372799.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02372799.